Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Roche signs $1bn-plus cancer deal with Molecular Partners

Roche signs $1bn-plus cancer deal with Molecular Partners time to re-treatment and with signs that inflammation in the eye could be worse than with rival treatment Lucentis (ranibizumab) from Roche.

NICE backs two eye treatments

NICE backs two eye treatments NICE, which provides guidance on the cost-effectiveness of treatments for NHS use, published final guidance backing both a new indication for Novartis' eye drug Lucentis (ranibizumab) and Alimera Sciences' intravitreal ... As per the Lucentis guidance,

Scotland first in UK to back Pfizer's Inlyta

Scotland first in UK to back Pfizer's Inlyta month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

Bayer files Eylea for diabetes complication in EU

Bayer files Eylea for diabetes complication in EU Looks to keep with Novartis’ Lucentis.  . Bayer is trying to win approval for a third indication for its big-selling eye disease treatment Eylea, namely the treatment of diabetic macular edema ... Eylea has a slight dosing advantage over Lucentis as

Novartis' Lucentis wins fourth NICE recommendation

Novartis' Lucentis wins fourth NICE recommendation Even more NHS patients in England and Wales are set to have access to Novartis' Lucentis after the drug was backed as the first medicine recommended to treat leaking blood vessels ... NICE's appraisal committee agreed that Lucentis was superior to

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics